Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Bunse, Mario Dr. (1) Daniel, Peter Prof. Dr. (2) Kammertöns, Thomas Dr. (4) Kopp, Joachim Dr. (2) Leisegang, Matthias Prof. Dr. rer. nat. (3) Pezzutto, Antonio Prof. Dr. (2) Siffrin, Volker (1) Uckert, Wolfgang Prof. Dr. (6) Willimsky, Gerald Dr. (2) (-) Blankenstein, Thomas Prof. Dr. (13) Biologie maligner Lymphome (13) (-) Molekulare Immunologie und Gentherapie (13) Systembiologie von Gen-regulatorischen Elementen (1) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1996 (6) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) 2004 (8) 2005 (10) 2006 (1) (-) 2007 (5) 2008 (5) 2009 (2) 2010 (7) (-) 2011 (5) 2012 (6) 2013 (11) 2014 (3) (-) 2015 (3) 2016 (4) 2017 (6) 2018 (4) 2019 (6) 2021 (4) 2022 (6) 2023 (4) 2024 (2) 13 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Molekulare Immunologie und Gentherapie 200720112015 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. Januar 2007 / J Immunother T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging R. Agger M.S. Petersen C.C. Petersen S.B. Hansen H. Stodkilde-Jorgensen U. Skands T. Blankenstein T.E. Andersen E.F. Hulgaard J.T. Jorgensen J. Marqversen H.J. Gundersen M.E. Hokland 15. Oktober 2007 / J Immunol Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity M. Weinhold D. Sommermeyer W. Uckert T. Blankenstein 01. Dezember 2007 / Immunol Rev The adaptive immune response to sporadic cancer G. Willimsky T. Blankenstein 01. August 2007 / Semin Cancer Biol Do autochthonous tumors interfere with effector T cell responses? T. Blankenstein 01. Oktober 2007 / Gene Ther In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine S. Cayeux B. Bukarica C. Buschow J. Charo M. Bunse B. Doerken T. Blankenstein 15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens 01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto 28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein 01. November 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein 13. Dezember 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
01. Januar 2007 / J Immunother T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging R. Agger M.S. Petersen C.C. Petersen S.B. Hansen H. Stodkilde-Jorgensen U. Skands T. Blankenstein T.E. Andersen E.F. Hulgaard J.T. Jorgensen J. Marqversen H.J. Gundersen M.E. Hokland
15. Oktober 2007 / J Immunol Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity M. Weinhold D. Sommermeyer W. Uckert T. Blankenstein
01. Dezember 2007 / Immunol Rev The adaptive immune response to sporadic cancer G. Willimsky T. Blankenstein
01. August 2007 / Semin Cancer Biol Do autochthonous tumors interfere with effector T cell responses? T. Blankenstein
01. Oktober 2007 / Gene Ther In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine S. Cayeux B. Bukarica C. Buschow J. Charo M. Bunse B. Doerken T. Blankenstein
15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
01. November 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein
13. Dezember 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein